Drug Trial Radar · NCT05579860
A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: May 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
104
Actual
Start
Oct 5, 2022
Primary completion
May 22, 2023
Study completion May 22, 2023
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- Oct 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the bioequivalence of olezarsen between 2 subcutaneous (SC) formulations \[(autoinjector (AI) and vial\] at 2 dose levels in healthy adult participants.
Conditions
- Healthy Participants
Interventions
OlezarsenDrug
Olezarsen will be administered by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration-time curve (AUC) of olezarsen from time 0 to 336 hours (AUC0-336h)Time frame: Up to Day 8 of each of Treatment Periods 1 and 2
- Maximum plasma concentration of olezarsen (Cmax)Time frame: Up to Day 91 of Treatment Period 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medpace Clinical Pharmacology Unit
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.